Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Enveric Biosciences Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.5 (market cap $4.71B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.69M). The key difference: Definium Therapeutics Inc. Common Shares is far larger — about 704× Enveric Biosciences Inc's market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Enveric Biosciences Inc for 14 Days on average.
| DFTX | ENVB | |
|---|---|---|
Market Cap | $4.71B | $6.69M |
Volume | 1,966,636 | 41,141 |
Sector | Health | Health |
52-Week High | $48.45 | $10.80 |
52-Week Low | $10.68 | $1.27 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $3.67B | -$1.60M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
